These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 25881614)

  • 1. Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy.
    Huhn GD; Sigman A; Livak B
    Antivir Ther; 2015; 20(8):849-54. PubMed ID: 25881614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
    Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
    HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
    Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F
    HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
    AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.
    Cahn P; Fourie J; Grinsztejn B; Hodder S; Molina JM; Ruxrungtham K; Workman C; Van De Casteele T; De Doncker P; Lathouwers E; Tomaka F
    AIDS; 2011 Apr; 25(7):929-39. PubMed ID: 21346512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial.
    Santos JR; Llibre JM; Bravo I; García-Rosado D; Cañadas MP; Pérez-Álvarez N; Paredes R; Clotet B; Moltó J
    AIDS Res Hum Retroviruses; 2016 May; 32(5):452-5. PubMed ID: 26781004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients.
    Lathouwers E; De La Rosa G; Van de Casteele T; Baeten B; Tomaka F; De Meyer S; Picchio G
    Antivir Ther; 2013; 18(3):289-300. PubMed ID: 23558157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.
    Arribas JR; Horban A; Gerstoft J; Fätkenheuer G; Nelson M; Clumeck N; Pulido F; Hill A; van Delft Y; Stark T; Moecklinghoff C
    AIDS; 2010 Jan; 24(2):223-30. PubMed ID: 20010070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
    Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
    AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.
    Arribas JR; Clumeck N; Nelson M; Hill A; van Delft Y; Moecklinghoff C
    HIV Med; 2012 Aug; 13(7):398-405. PubMed ID: 22413874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
    Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
    HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial.
    Girard PM; Antinori A; Arribas JR; Ripamonti D; Bicer C; Netzle-Sveine B; Hadacek B; Moecklinghoff C
    HIV Med; 2017 Jan; 18(1):5-12. PubMed ID: 27279571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study.
    Antinori A; Meraviglia P; Monforte Ad; Castagna A; Mussini C; Bini T; Gianotti N; Rusconi S; Colella E; Airoldi G; Mancusi D; Termini R
    Drug Des Devel Ther; 2016; 10():1589-603. PubMed ID: 27226708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.
    Overton ET; Tebas P; Coate B; Ryan R; Perniciaro A; Dayaram YK; De La Rosa G; Baugh BP
    HIV Clin Trials; 2016 Mar; 17(2):72-7. PubMed ID: 26917112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data.
    Capetti AF; Cossu MV; Orofino G; Sterrantino G; Cenderello G; De Socio GV; Cattelan AM; Soria A; Rusconi S; Riccardi N; Baldin GM; Niero FP; Barbarini G; Rizzardini G
    BMC Infect Dis; 2017 Sep; 17(1):658. PubMed ID: 28964268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.
    Moltó J; Valle M; Santos JR; Mothe B; Miranda C; Cedeño S; Negredo E; Yritia M; Videla S; Barbanoj MJ; Clotet B
    Antivir Ther; 2010; 15(2):219-25. PubMed ID: 20386077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.
    Ghosn J; Slama L; Chermak A; Houssaini A; Lambert-Niclot S; Schneider L; Fourn E; Duvivier C; Simon A; Courbon E; Murphy R; Flandre P; Peytavin G; Katlama C;
    J Med Virol; 2013 Jan; 85(1):8-15. PubMed ID: 23024008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial.
    Geretti AM; Arribas JR; Lathouwers E; Foster GM; Yakoob R; Kinloch S; Hill A; van Delft Y; Moecklinghoff C
    HIV Clin Trials; 2013; 14(1):45-50. PubMed ID: 23372114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.
    Arastéh K; Yeni P; Pozniak A; Grinsztejn B; Jayaweera D; Roberts A; Hoy J; De Meyer S; Vangeneugden T; Tomaka F
    Antivir Ther; 2009; 14(6):859-64. PubMed ID: 19812449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term clinical experience with darunavir (2007-2015) in a large cohort of HIV-infected patients in Spain.
    Pernas B; Grandal M; Tabernilla A; Cid P; Pértega S; Castro-Iglesias Á; Mena Á; Margusino L; Pedreira JD; Poveda E
    J Med Virol; 2016 Dec; 88(12):2125-2131. PubMed ID: 27218208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.